The abstract is read at the publisher; the summary is JClub's.
In the ANNEXa-I trial cohort of 434 patients with factor Xa inhibitor–associated intracerebral hemorrhage, hematoma expansion occurred in 31.8% and was linked to specific NCCT markers.
- Why it matters: Clinicians need early imaging signals to flag which FXai-associated ICH patients are most likely to experience hematoma expansion and may benefit from targeted reversal.
- What they did: This post hoc analysis assessed non-contrast CT markers—heterogeneous density, hypodensity, and the black hole sign—and evaluated whether andexanet’s effect on hematoma expansion was consistent across marker-defined subgroups.
- The result: At least one NCCT marker appeared in 72.1%, and heterogeneous density, hypodensity, and the black hole sign were independently associated with hematoma expansion, supporting NCCT risk stratification in FXai-associated ICH.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.